Biovest International, Inc.
(763) 786-0302
8500 Evergreen Blvd.
Minneapolis, Minnesota,
USA
55433
biovest international
- Year Established:
- 1981
Products & Services
-
- Cancer Vaccine; Non-hodgin's Lymphoma; Cancer Therapy; Immunotherapy; Cancer Idiotype; Lymphoma; Cancer Vaccine; Persoanalized Medicine;
Web Result
- Phase III Clinical Trial...
- Main Menu HomeAbout BiovestCorporate ProfileManagement Team & DirectorsScientific Advisory BoardCollaborations & PartneringCareersCancer Vaccine TechnologyBiovaxID Personalized Cancer VaccineBiovaxID PublicationsPhase III Isotype AnalysisPhase III Clinical Trial SummaryAutovaxID Cell Culture Instruments & ServicesBioreactor SystemsContract ManufacturingCustomer ServiceInvestor Relati...
- BiovaxID Personalized Cancer Vaccine
- BiovaxID Personalized Cancer Vaccine Written by Administrator Thursday, 13 January 2011 18:45 Targeting the Treatment of Certain B-Cell Lymphomas including Follicular Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma What is a Personalized Cancer Vaccine? Unlike a preventative vaccine, such as for measles or mumps, BiovaxID is administered as a cancer treatment, designed to stimulate and "train" the...
- Contract Manufacturing
- Contract Manufacturing Written by Administrator Monday, 21 June 2010 20:44 Your Partner for cGMP Biologics Manufacturing With nearly 30 years of expert experience in cell culture, Biovest will formulate the optimal strategy for your biologics manufacturing. By accurately matching the level of hollow-fiber production technology to your Phase of product development, our clients can manage their ov...
- Cancer Vaccine Technology
- Main Menu HomeAbout BiovestCorporate ProfileManagement Team & DirectorsScientific Advisory BoardCollaborations & PartneringCareersCancer Vaccine TechnologyBiovaxID Personalized Cancer VaccineBiovaxID PublicationsPhase III Isotype AnalysisPhase III Clinical Trial SummaryAutovaxID Cell Culture Instruments & ServicesBioreactor SystemsContract ManufacturingCustomer ServiceInvestor Relati...
- BiovaxID Phase III Isotype Analysis (IgM versus IgG)
- BiovaxID Phase III Isotype Analysis (IgM versus IgG) Written by Administrator Friday, 14 January 2011 16:11 At the 2010 American Society of Hematology (ASH) Annual Meeting, Biovest presented an updated Phase III data analysis for BiovaxID which strongly suggests that the improved disease-free survival observed in BiovaxID-treated patients depends on an integral tumor protein fragment administered ...
Website Links:
Biovest International, Inc. | About Biovest | AutovaxID | BiovaxID Publications | Cancer Vaccine Technology | Cell Culture Instruments... | Collaborations & Partnering | Contract Manufacturing | Interview with MD Anderson's... | Management Team & Directors | Media Center | Personalized Cancer Vaccine | Phase III Clinical Trial... | Phase III Isotype Analysis | Scientific Advisory Board
Own this business?
Request to update the information